Print

A U.S. Food and Drug Administration (FDA) panel voted that the COX-2 inhibitor celecoxib poses no greater risk for heart attack and stroke than ibuprofen or naproxen.

Celecoxib has been viewed as a safety risk since similar drugs rofecoxib and valdecoxib were removed from the market in 2004 and 2005 respectively. National Public Radio notes that, based on the committee's conclusion, FDA may update advice regarding the safety of celecoxib. Although the agency is not required to follow the advice of advisory panels, it usually does. Learn more...